<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020652</url>
  </required_header>
  <id_info>
    <org_study_id>TQ05105-II-01</org_study_id>
    <nct_id>NCT05020652</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis</brief_title>
  <official_title>A Randomized, Double Blind, Double Dummy, Parallel Controlled, Multicenter Phase II Clinical Trial of TQ05105 Tablets Versus Hydroxyurea Tablets in the Treatment of Moderate and High Risk Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target&#xD;
      related diseases, such as moderate or high-risk multiple myelofibrosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spleen Volume was Reduced by more than 35% from baseline（SVR35） assessed by Independent Review Committee (IRC)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Proportion of subjects whose spleen volume was reduced by more than 35% from baseline at the end of week 24 of IRC assessment (SVR35)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR35 assessed by the researchers and objective response rate (ORR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Proportion of subjects whose spleen volume was reduced by more than 35% from baseline to the end of the 24th week assessed by the researchers and ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optimal response rate of splenic response</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>Proportion of subjects with at least one reduction in spleen volume ≥ 35% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>onset time of splenic response</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>The time between the date of randomization and the date when the spleen volume decreased ≥ 35% from the baseline for the first time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Maintenance of a Least 35% Reduction in Spleen Volume(DoMSR)</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>Duration of spleen volume reduction ≥ 35% from baseline (domsr): the time between the date when the spleen volume reduction ≥ 35% from baseline occurs for the first time and the date when the spleen volume reduction &lt; 35% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects whose total symptom score of Myeloproliferative neoplasm- Symptom Assessment Form- Total Symptom Score(MPN-SAF TSS) decreased by more than 50% compared with baseline</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>At the 24th week, the proportion of subjects whose total symptom score of MPN-SAF TSS) decreased by more than 50% compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total symptom score of MPN-SAF TSS decreased compared with baseline</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The total symptom score of MPN-SAF TSS decreased compared with baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>The interval from the random date to the date of occurrence of any of the following events, whichever occurs first: ① the spleen volume increases by ≥ 25% compared with the lowest value during the treatment period (including the screening period); ② Death from any cause; ③ Start other anti-MF treatments;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival (LFS)</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>The time interval between the random date and the date of any of the following events, whichever occurs first, shall prevail: ① the date when the first bone marrow smear showed that the number of primordial cells was more than or equal to 20%; ② The first peripheral blood smear showed that the number of primordial cells was more than or equal to 20% and the absolute value of primordial cells was more than or equal to 1% × 10^9 / L for at least 2 weeks; ③ Death from any cause;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>The time interval between the random date and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events (AEs) occurred during the study</measure>
    <time_frame>up to 120 weeks</time_frame>
    <description>The incidence and severity of AEs occurred during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Moderate and High Risk Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>TQ05105 tablets + Hydroxyurea blank tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take TQ05105 Tablets + Hydroxyurea blank tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQ05105 blank tablets + Hydroxyurea tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take TQ05105 blank tablets + Hydroxyurea tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ05105 tablets</intervention_name>
    <description>TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.</description>
    <arm_group_label>TQ05105 tablets + Hydroxyurea blank tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxycarbamide tablets</intervention_name>
    <description>Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.</description>
    <arm_group_label>TQ05105 blank tablets + Hydroxyurea tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subjects volunteered to join the study and signed informed consent, with good&#xD;
             compliance;&#xD;
&#xD;
          2. Age: 18-75 years old (when signing the informed consent form); Eastern Cooperative&#xD;
             oncology Group (ECoG) Performance Status (PS) score: 0-2; The expected survival time&#xD;
             is more than 24 weeks;&#xD;
&#xD;
          3. Primary Myelofibrosis (PMF) was diagnosed according to World Health Organization (WHO)&#xD;
             standard (2016 Edition), or Post Polycythemia Vera(PV)-MF or Post Essential&#xD;
             Thrombocythemia (ET)-MF was diagnosed according to International Working&#xD;
             Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) standard; JAK2&#xD;
             mutation or not was included in the study;&#xD;
&#xD;
          4. According to Dynamic International Prognostic Scoring System (DIPSS) prognosis grading&#xD;
             criteria, the patients with myelofibrosis were assessed as medium risk (including&#xD;
             medium risk-1, medium risk-2) or high risk;&#xD;
&#xD;
          5. Splenomegaly: palpate the splenic margin at least 5cm below the ribs (the distance&#xD;
             from the costal margin to the farthest point of splenic protrusion);&#xD;
&#xD;
          6. Peripheral blood primordial cells ≤ 10%;&#xD;
&#xD;
          7. If anti myelofibrosis therapy (except JAK inhibitor) is being received before&#xD;
             screening, the drug must be stopped at least 4 weeks before the random date;&#xD;
&#xD;
          8. No growth factor, colony stimulating factor, thrombopoietin or platelet transfusion&#xD;
             was received within 2 weeks before the examination, and hemoglobin (Hgb) ≥ 80g / L,&#xD;
             platelet count (PLT) ≥ 100 within 7 days before the random date × 10^9 / L and&#xD;
             neutrophil absolute value (neut) ≥ 1.0 × 10^9/L;&#xD;
&#xD;
          9. The main organs were functional 7 days before the random date, which was in accordance&#xD;
             with the following criteria: Total Bilirubin (TBIL) was less than 2 times the upper&#xD;
             limit of normal value (ULN); Alanine aminotransferase (ALT) and Aspartate&#xD;
             aminotransferase (AST) were less than 2.5 times of ULN; Serum creatinine (Cr) &lt; 1.5&#xD;
             times of ULN or creatinine clearance rate (Ccr) ≥ 50ml/min; The blood coagulation&#xD;
             function should be checked in accordance with: prothrombin time (PT), activated&#xD;
             partial thromboplastin time (APTT), international standardized ratio (INR) &lt; 1.5 × ULN&#xD;
             (not anticoagulant treatment); Left ventricular ejection fraction (LVEF) evaluated by&#xD;
             color Doppler ultrasonography ≥ 50%;&#xD;
&#xD;
         10. Female subjects of childbearing age should agree to use contraceptive measures (such&#xD;
             as intrauterine device, contraceptive or condom) during the study period and within 6&#xD;
             months after the end of the study; The serum pregnancy test was negative within 7 days&#xD;
             before the date of randomization and must be non lactating subjects; Male subjects&#xD;
             should agree to use contraception during the study period and within 6 months after&#xD;
             the end of the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have received allogeneic stem cell transplantation in the past, or&#xD;
             autologous stem cell transplantation within 3 months before the random date, or&#xD;
             recently planned stem cell transplantation;&#xD;
&#xD;
          2. Patients who have received JAK inhibitors in the past;&#xD;
&#xD;
          3. Those who had undergone splenectomy or received splenic radiotherapy within 6 months&#xD;
             before the date of randomization (including internal and external radiotherapy);&#xD;
&#xD;
          4. Other malignancies were present or present within 3 years before the date of&#xD;
             randomization. The following two cases can be included: other malignant tumors treated&#xD;
             by single operation have achieved 5-year disease-free survival (DFS) in a row; Cured&#xD;
             cervical carcinoma in situ, non melanoma skin cancer and superficial bladder tumor [ta&#xD;
             (non-invasive tumor), tis (carcinoma in situ) and T1 (tumor infiltrating basement&#xD;
             membrane)];&#xD;
&#xD;
          5. Patients with multiple factors (such as inability to swallow, postoperative&#xD;
             gastrointestinal resection, acute and chronic diarrhea, intestinal obstruction, etc.)&#xD;
             affecting oral or absorption of drugs;&#xD;
&#xD;
          6. Non hematological toxicity caused by previous treatment did not return to ≤ 1&#xD;
             (excluding alopecia);&#xD;
&#xD;
          7. Patients who received major surgical treatment or had obvious traumatic injury within&#xD;
             4 weeks before the date of randomization;&#xD;
&#xD;
          8. At present, there are congenital bleeding or coagulation diseases, or are using&#xD;
             anticoagulant therapy;&#xD;
&#xD;
          9. Arteriovenous thrombotic events occurred within 6 months before the random date, such&#xD;
             as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage,&#xD;
             cerebral infarction), deep venous thrombosis and pulmonary embolism;&#xD;
&#xD;
         10. A history of psychotropic substance abuse or mental disorder;&#xD;
&#xD;
         11. Active or uncontrolled severe infection (≥ Common Terminology Criteria for Adverse&#xD;
             Events(CTCAE)2 infection);&#xD;
&#xD;
         12. Hepatitis B Virus (HBV) DNA≥ULN； Hepatitis C antibody positive and Hepatitis C Virus&#xD;
             (HCV) RNA ≥ ULN;&#xD;
&#xD;
         13. Myocardial ischemia or myocardial infarction, arrhythmia, QT interval prolongation&#xD;
             (corrected QT interval (QTc) ≥ 450 ms for male, QTc ≥ 470 ms for female) and&#xD;
             congestive heart failure (NYHA classification) of grade 2 or above;&#xD;
&#xD;
         14. Blood pressure control is not ideal (systolic blood pressure ≥ 150 mmHg or diastolic&#xD;
             blood pressure ≥ 100 mmHg);&#xD;
&#xD;
         15. Renal failure requires hemodialysis or peritoneal dialysis;&#xD;
&#xD;
         16. Newly diagnosed pulmonary fibrosis or drug-related interstitial lung disease within 3&#xD;
             months before the date of randomization;&#xD;
&#xD;
         17. History of immunodeficiency, including Human Immunodeficiency Virus (HIV) positive or&#xD;
             other acquired or congenital immunodeficiency diseases, or organ transplantation;&#xD;
&#xD;
         18. Patients with epilepsy and need treatment;&#xD;
&#xD;
         19. Had received chemotherapy, radiotherapy or other anti-cancer therapy within 4 weeks&#xD;
             before the date of randomization;&#xD;
&#xD;
         20. Within 2 weeks before the date of randomization, he received Chinese patent medicines&#xD;
             (including compound cantharis capsule, Kang'ai injection, kang'laite capsule /&#xD;
             injection, Aidi injection, Brucea javanica oil injection / capsule, Xiaoaiping tablet&#xD;
             / injection, cinobufagin capsule, etc.) with anti-tumor indications specified in nmpa&#xD;
             approved drug instructions;&#xD;
&#xD;
         21. Uncontrolled pleural effusion, pericardial effusion or ascites;&#xD;
&#xD;
         22. Patients with central nervous system involvement;&#xD;
&#xD;
         23. There was a history of live attenuated vaccine inoculation within 4 weeks before the&#xD;
             date of randomization or live attenuated vaccine inoculation was planned during the&#xD;
             study period;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhijian Xiao, Doctor</last_name>
    <phone>022-23909184</phone>
    <email>zjxiao@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Minghui Duan, Doctor</last_name>
      <phone>13621262462</phone>
      <email>mhduan@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Peoples Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510055</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Du, Doctor</last_name>
      <phone>13826271560</phone>
      <email>xindu_ggh@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China School of Medicine / West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ling Pan, Doctor</last_name>
      <phone>028-85423046</phone>
      <email>lingpan20002000@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hostpital, Chinese Academy of medical sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhijian Xiao, Doctor</last_name>
      <phone>022-23909184</phone>
      <email>zjxiao@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

